DOCSLIB.ORG

1 Azbil Telstar Tecnologies S.L.U

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Azbil Telstar Tecnologies S.L.U AZBIL TELSTAR TECHNOLOGIES, S.L.U. 1 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AUDIT PLAN 2020 AZBIL TELSTAR TECNOLOGIES S.L.U Manufacturer Country Address AARTI INDUSTRIES LTD. India Unit IV - Plot No. E-50, MIDC, Tarapur, Tal-Palghar Dist. Thane, Maharashtra 401506 - India Commercial Hub road,Near APIIC Pump House,Plot No:2, Road No:21,J.N.Pharma City (Ramky),Tadi ACACIA LIFE SCIENCES Pvt. Ltd. (BIOCON) India Village, IDA Paravada,Visakhapatnam, India - 531 021 Unit-III Plot No. 842-843, Village-Karakhadi, Taluk-Padra, District-Panchmahal, Vadodara-391 450, ALEMBIC PHARMACEUTICALS LTD. India Gujarat, INDIA ALEMBIC PHARMACEUTICALS LTD. India Village Panelav, Near Baska. Taluka Halol, District Panchmahal - 389 350 Gujarat - India AMI LIFE SCIENCES PVT. LTD. India Block No 82/B, ECP Road, At & Post : Karakhadi-391 450 Ta: Padra, Dist. Baroda, Gujarat, INDIA. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. AMINO CHEMICALS (MOEHS) Malta MRA 050X, Industrial Estate. Marsa MRS 3000 Malta. ANUGRAHA CHEMICALS India D-46-50 &C-62 & 63 KSSIDC Indl Estate Doddaballpura, Bangalore 561 203 INDIA Nº D47 to D50, C62 & C 63, KSSIDC Industrial State, Doddaballapur, Bangalore, Karnataka, 561203 ANUGRAHA CHEMICALS India INDIA ARCH UK BIOCIDES UK Wheldon Road, Castelford, West Yorkshire - WF 102JT, England Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 2 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 AURO LABORATORIES LIMITED India K-56, M.I.D.C. Tarapur, Boisar, Dist. Thane, Maharashtra – 401 506, INDIA AUROBINDO UNIT IX India Unit IX. Survey Nº 374 Gundlamachanoor, Hathnoora, Medak- 502 296, Telangana, India Unit VIII: Survey No.: 10 & 13 I.D.A. Kazipally, Jinnaram Mandal, Medak District, Gaddapotharam AUROBINDO UNIT VIII India Village, Telangana- 502 319 India. Unit VIII Survey Nº 13, I.D.A. Kazipally, Medak District Jinnaram Mandal, 502319 Gaddapotharam AUROBINDO UNIT VIII India Village, Andhra Pradesh - India Unit- XI, Survey Nº 61-66, IDA Srikakulam District, Ranasthalam Mandal, Pydibhimavaram village, AUROBINDO UNIT XI India Andhra Pradesh, India- 532409 Unit- XI, Survey Nº 61-66, IDA Srikakulam District, Ranasthalam Mandal, Pydibhimavaram village, AUROBINDO UNIT XI India Andhra Pradesh, India- 532409 BAYER HISPANIA, S.L. Spain Sabino Alonso Fueyo 77 E - 33930 - La Felguera (Asturias) -Spain BENECHIM, S.P.R.L. BELGIUM Rue René Magritte, 163, 7860 Lessines, Belgium M/s Benzo Chem Industries Pvt Limited, W-24, MIDC, Chemical Zone, Ambernath (W), Maharashtra – BENZO CHEM INDUSTRIES PVT LIMITED India 421 501, India. CADILA HEALTHCARE LIMITED India Unit II: 5-1/B, G.I.D.C. Industrial Estate., Ankleshwar- Gujarat- India - 393 002 CHANGZHOU SUNLIGHT PHARMACEUTICAL CO. LTD. CHINA No 7 Daqiao South Road, Jiuli Street Benniu Town, China 213 134 Changzhou City, Jiangsu Province, China Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 3 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 CHONGQING DAXIN PHARMACEUTICAL CHINA No.21, Founder Road, Shuitu Town, Beibei District, Chongqing 400714, China CHONGQING DAXIN PHARMACEUTICAL CHINA No.21 Founder road, Shuitu town, BeiBei district, Chongqing 400714, China CIPLA LIMITED India PLOT, Nº D-7, D-27 MIDC, INDUSTRIAL AREA, KURKUMBH VILLAGE (POONA, MAHARASHTRA) INDIA PLOT, Nº D-7, , D-27 MIDC, INDUSTRIAL AREA, KURKUMBH VILLAGE (POONA, MAHARASHTRA) CIPLA LIMITED India INDIA CIPLA LIMITED India Unit II: Plot No L-139, S-103 & M-62. Verna Industrial Estate, Verna, Goa IN-403 722. INDIA DAFENG JINGYUAN CHINA West Jing Yi Road, Soth District of Ocean Economic Development Park - Dafeng, Jiangsu, China CTO-SEZ Process Unit-01, Sector No. 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survery No. 57 to 58, 60, DR. REDDY'S India 72 to 73, 76 to 77 & 80, Devunipalavalsa Village, Ranasthalam Mandal, Srikakulam District, 532409, Andhrapradesh, India Steanard Lane, Mirfield, West Yorkshire - WF14 8HZ (UK) DR. REDDY'S LABORATORIES LIMITED UK Plot No. 137, 138, 145 &146, S.V. Co-Op, Industrial Estate, Bollaram, Jinnaram Mandal, Sangareddy DR. REDDY'S UNIT I India District, Telangana State, India 502 325 EIGENMANN & VERONELLI SPAIN Miguel Hernández, 42-44. Pol. Ind. LA Pedrosa 08908 L’Hospitalet de Llobregat (Barcelona) Spain ELEMENTIS PHARMA GMBH (FORMERLY BK Germany Giulinistrasse 2, Ludwigshafen/Rhein, D-67065, Germany GIULINI GmbH) Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 4 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 ELEMENTIS SPECIALTIES UK Nettlehill Road, Houston Industrial Estate, Livingston, West Lothian, EH54 5DL, Scotland NO.6 ZHONGJING ROAD, ZHONGSHAN TORCH HI-TECH INDUSTRIAL DEVELOPMENT ZONE, ENANTIOTECH CORPORATION LIMITED China ZHONGSHAN CITY, GUANGDONG PROVINCE, CHINA ESSENTRA PACKAGING, S.A. SPAIN Calle Fusters, 18 P.I. can Cuyás, 08110 Montcada i Reixac, Barcelona - Spain ESTEVE PHARMACEUTICALS, S.A. SPAIN C/ De San Martí, 75-97; 08107 Martorelles (Barcelona) Spain Ethypharm, S.A. France Chemin de la Poudrière BP117, 76121 Le Grand-Quevilly Cedex, France Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri East, Mumbai, Glenmark India Maharashtra 400099, India GLENMARK PHARMA LTD. India Plot nº Z-103-I, SEZ Phase II, Dahej, Taluka Vagra, District Bharuch, Gujarat- 392 130, India GLENMARK PHARMACEUTICALS LIMITED INDIA Plot Nº Z-103-I, SEZ Phase II, Dahej, Taluka Vagra, District Bharuch, Gujarat, 392130 India Plot No.8, Jawaharlal Nehru pharma City, Unit ll, TadiVillage, parawada Mandal lndia-531-019 GRANULES INDIA LIMITED India Visakhapatnam, India Plot No. 160/A, 161/E, 162 & 174/A, Gagillapur Village, Dundigal - Gandimaisamma Manda!, Medchal GRANULES INDIA LIMITED India Malka·iri Telangana State, Hyderabad, 500043 India GUANDONG RAFFLES PHARMA TECH CHINA No.3, Binhai 10th Road North, Daya Bay, Huizhou, Guangdong, China, 516081 Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 5 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 HANGZHOU THINK CHEMICAL, Co. Ltd. China Yucai Road, Zouqu Town, Changzhou, China HEBEI JIHENG (GROUP) PHARMACEUTICAL Xijingming Village, Donganzhuang Township, Shenzhou Cuonty, Hengshui City, Hebei Province 053800 CHINA CO., LTD China 82/A KIADB Industrial Area , Jigani, Anekal Taluk - 562105 Bangalore - India HIKAL LIMITED India HUBEI GRANULES BIOCAUSE No. 132 Yangwan Road (Jingmen City, Hubei Province) - 448000 - China China PHARMACEUTICAL CO., LTD HUNAN YUXIN PHARMACEUTICAL CO. LTD. China Longxutang, Shaoyang, Hunan Province, 422001 P.R.China. Indo German Alkaloids (Inga) India Plot No. B-1 (pt), Phase II, Zone-A, MEPZ-Special Economic zone, NH-45 Tambaram, Chennai, 600045 INTAS India Plot nº 457-458, Sharkhej-Bavia Hihgway, Matoda 382 210 Gujarat - India INTAS PHARMACEUTICALS LTD. India Plot No. 457 and 458, Sarkhej-Bavla highway, Matoda 382210, Gujarat, INDIA (MATODA site) JINGMEN XIONGXING CHEMICAL CO LTD CHINA Shayang Economic Development Zone, Shayang County, Jingmen, Hubei, China JINNENG SCIENCE AND TECHNOLOGY CHINA No. 1 West Road, Industrial Park, Qihe, Shandong, China KOÇAC PHARMA Turkey KOÇAK FARMA ORGANIZE SANAYI BÓLGESI CERKEZKÓY, TEKIRDAG - TURKEY Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 6 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 LANXESS SOLUTIONS US INC (antes USA 2226 Haynesville HWY, El Dorado AR 71730 CHEMTURA CORPORATION) LIANYUNGANG CHONGLONG FINE CHEMICAL CHINA Duigou Chemical Zone, Guannan, Lianyungang, Jiangsu, China CO LTD LIANYUNGANG HENGFEI PHARMACEUTICAL China Guannan (Chemical Industrial Park) Lianyungang City, Duigougang 222523, Jiangsu Province, China CO. LTD LIANYUNGANG KANGLE PHARMACEUTICAL CO. No.2, China Road, Gan Yu Economy Development Zone,Lianyungang CHINA LTD. Jiangsu Province, China MALLADI India Unit III - Ranipet, Tamil Nadu - India MALLINCKRODT USA Raleigh Pharmaceutical Plant, 8801 Capilat Boulevard, Raleigh NC 27616 USA PHARMACEUTICALS ( SpecGx LLC) MELODY HEALTHCARE PVT. LTD. India Plot No. J 73, M.I.D.C Tarapur, Boisar, Dist. Phalgar-401506 Maharashtra, India MOEHS BCN SPAIN Polígono industrial Aquiberia, Zenc 12, 08755 Castellbisbal (Barcelona) Spain MOEHS CÁNTABRA, S.L. SPAIN Polígono Industrial Requejada, 39313 Polanco (Cantabria), Spain MOEHS CÁNTABRA, S.L. SPAIN Polígono Industrial Requejada, 39313 Polanco (Cantabria), Spain Plot No. 212/A, B, C, D IDA, Phase-II, Pashamylaram, Patancheru (Mandal) Medak District (502307) MSN Pharmachem Private Ltd India Andhra Pradesh - INDIA Consultancy Department March_2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. 7 www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 Plot No- 212/A/B/C/D, IDA, Phase-II, Pashamylaram (Village), Patancheru (Mandal), Sangareddy MSN PHARMACHEM PVT LTD India (District)- 502329, Telangana - India Unit IX - Plot Nº 5, Road Nº.12.J.N. Pharma City. Tadi Village, Parawada Mandal, Vishakhapatnam. MYLAN UNIT IX India Andhra Pradesh, India. Unit IX - Plot Nº 5, Road Nº.12.J.N. Pharma City. Tadi Village, Parawada Mandal, Vishakhapatnam. MYLAN UNIT IX India Andhra Pradesh, India. UNIT VII - Plot No. 14, 99 & 100, Phase II, IDA, Pashamylaram, Patancheru (M), Medak District – 502 MYLAN UNIT VII India 307, Andhra Pradesh, India Unit VII - Plot No. 14, 99 & 100 Phase II, IDA Pashamylaram, Patancheur (M), Medak District 502307 MYLAN UNIT VII India Telangana, INDIA Unit XI - Plot No. 1 A/2, MIDC Industrial Estate, Taloja, Panvel District, Raigad,
Load more

Recommended publications
  • Alembic Pharmaceuticals Limited
    Placement Document Not for Circulation and Strictly Confidential Serial Number: ___ ALEMBIC PHARMACEUTICALS LIMITED Registered and Corporate Office: Alembic Road, Vadodara 390 003, Gujarat, India Telephone: +91 265 228 0550; Fax: +91 265 228 2506 E-mail: [email protected]; Website: www.alembicpharmacueticals.com; CIN: L24230GJ2010PLC061123 Alembic Pharmaceuticals Limited (our “Company" or the “Issuer”) was originally incorporated on June 16, 2010 as “Alembic Pharma Limited”, a public limited company under the Companies Act, 1956. Thereafter, our Company commenced its business on July 1, 2010, pursuant to a certificate of commencement of business issued to it by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the name of our Company was changed to “Alembic Pharmaceuticals Limited”, pursuant to a fresh certificate of incorporation consequent upon change of name dated March 12, 2011, issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. For details with respect to changes to the name of our Company, see "General Information" on page 179. Our Company is issuing 80,47,210 Equity Shares (as defined below) at a price of ₹932.00 per Equity Share (the “Issue Price”), including a premium of ₹930.00 per Equity Share, aggregating to approximately ₹750.00 crore (the “Issue”). For further details, see “Summary of the Issue” on page 29. THIS ISSUE IS BEING UNDERTAKEN IN RELIANCE UPON CHAPTER VI OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI REGULATIONS”) AND SECTION 42 OF THE COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (“COMPANIES ACT”) The equity shares of our Company, of face value of ₹ 2 each (the “Equity Shares”) are listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”).
    [Show full text]
  • Inner 11 Equity PE Fund
    Modera erate tely Mod High to H w te ig o ra h L de o M V e r y w H Tata Equity P/E Fund o i L g (An open ended equity scheme following a value investment strategy) h Riskometer Investors understand that their principal As on 31st May 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily invests at least 70% of the net assets in equity Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets shares whose rolling P/E ratio on past four quarter earnings Equity & Equity Related Total 458548.17 97.42 Leisure Services for individual companies is less than rolling P/E of the S&P Auto Jubilant Foodworks Ltd. 167000 5195.70 1.10 BSE SENSEX stocks. Bajaj Auto Ltd. 250800 10515.54 2.23 Minerals/Mining INVESTMENT OBJECTIVE Tata Motors Ltd. 3000000 9562.50 2.03 NMDC Ltd. 2600000 4735.90 1.01 The investment objective of the Scheme is to provide Escorts Ltd. 475484 5571.72 1.18 Pesticides reasonable and regular income and/or possible capital appreciation to its Unitholder. However, there is no Auto Ancillaries Rallis India Ltd. 2250000 7048.13 1.50 assurance or guarantee that the investment objective of the MRF Ltd. 10600 8865.99 1.88 Petroleum Products Scheme will be achieved. The scheme does not assure or Ceat Ltd. 308700 4081.01 0.87 Reliance Industries Ltd. 1715000 37049.15 7.87 guarantee any returns. Banks Pharmaceuticals DATE OF ALLOTMENT ICICI Bank Ltd.
    [Show full text]
  • Case 1:14-Cv-08074-JBS-KMW Document 186 Filed 09/25/15 Page
    Case 1:14-cv-08074-JBS-KMW Document 186 Filed 09/25/15 Page 1 of 25 PageID: <pageID> IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY OTSUKA PHARMACEUTICAL CO., LTD., HONORABLE JEROME B. SIMANDLE Plaintiff, v. Civil Action Nos. TORRENT PHARMACEUTICALS LIMITED, 14-1078 (JBS/KMW) INC., TORRENT PHARMA INC., and HETERO LABS LIMITED, 14-2982 (JBS/KMW) Defendants. 14-3168 (JBS/KMW) 14-3306 (JBS/KMW) OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff, 14-3996 (JBS/KMW) v. 14-4307 (JBS/KMW) ALEMBIC PHARMACEUTICALS LIMITED, 14-4508 (JBS/KMW) ALEMBIC LIMITED, ALEMBIC GLOBAL 14-4671 (JBS/KMW) HOLDING SA, and ALEMBIC 14-5537 (JBS/KMW) PHARMACEUTICALS INC., Defendants. 14-5876 (JBS/KMW) 14-5878 (JBS/KMW) OTSUKA PHARMACEUTICAL CO., LTD., 14-6158 (JBS/KMW) Plaintiff, 14-6397 (JBS/KMW) v. ZYDUS PHARMACEUTICALS USA, INC. and 14-6398 (JBS/KMW) CADILA HEALTHCARE LIMITED, 14-6890 (JBS/KMW) 14-7105 (JBS/KMW) Defendants. 14-7106 (JBS/KMW) OTSUKA PHARMACEUTICAL CO., LTD., 14-7252 (JBS/KMW) Plaintiff, 14-7405 (JBS/KMW) v. 14-8074 (JBS/KMW) AUROBINDO PHARMA LIMITED, AUROBINDO PHARMA USA, INC., and AUROLIFE PHARMA 14-8077 (JBS/KMW) LLC, 15-1585 (JBS/KMW) Defendants. 15-1716 (JBS/KMW) OTSUKA PHARMACEUTICAL CO., LTD., 15-161 (JBS/KMW) Plaintiff, v. INTAS PHARMACEUTICALS LIMITED, ACCORD MEMORANDUM OPINION REGARDING HEALTHCARE, INC., and HETERO LABS OTSUKA’s MOTIONS TO STRIKE LIMITED, Defendants. OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff, v. SUN PHARMACEUTICAL INDUSTRIES LTD., SUN PHARMA GLOBAL INC., SUN PHARMA GLOBAL FZE, SUN PHARMA USA, SUN PHARMACEUTICALS INDUSTRIES, INC., and CARACO PHARMACEUTICAL LABORATORIES, Defendants.
    [Show full text]
  • Alembic Pharmaceuticals
    2QFY2018 Result Update | Pharmaceutical November 21, 2017 Alembic Pharmaceuticals BUY Performance Highlights CMP `514 Target Price ‘600 Y/E March (` cr) 2QFY2018 1QFY2018 % chg (qoq) 2QFY2017 % chg (yoy) Investment Period 12months Net Sales 789 648 21.8 879 (10.2) Other Income 8 0 0.0 0 19075.0 Operating Profit 178 101 75.8 177 0.7 Stock Info Interest 0 1 (60.7) 1 (63.5) Sector Pharmaceutical Adj. Net Profit 122 67 82.2 120 1.4 Market Cap (` cr) 9,681 Source: Company, Angel Research Net Debt (` cr) -9 Alembic Pharma posted marginally lower than expected sales for 2QFY2018. In Beta 0.3 Rupee terms, revenues de-grew by 10.2% yoy to `789cr (`980cr expected) v/s. 52 Week High / Low 709/470 `879cr in 2QFY2017. International formulation came in at `262cr v/s. `352cr in Avg. Daily Volume 19,513 2QFY2017, a yoy dip of 26.0%. Indian formulation sales came in at `385cr v/s. `363cr Face Value (`) 2 in 2QFY2017, a yoy growth of 6.0%. On the operating front, EBITDA margin came BSE Sensex 33,343 in at 22.6% (15.4% expected) v/s. 20.3% in 2QFY2017, an expansion of 230bps yoy. Nifty 10,284 Thus, PAT came in at `122cr (`108cr expected) v/s. `120cr in 2QFY2017, up 1.4% Reuters Code ALEM.BO yoy. We recommend a Buy rating. Bloomberg Code ALPM@IN Results Highlights: In Rupee terms, revenues de-grew by 10.2% yoy to `789cr (`980cr expected) v/s. `879cr in 2QFY2017. International formulation came in at Shareholding Pattern (%) `262cr v/s.
    [Show full text]
  • Annual Report 2019
    HAITONG SECURITIES CO., LTD. 海通證券股份有限公司 Annual Report 2019 2019 年度報告 2019 年度報告 Annual Report CONTENTS Section I DEFINITIONS AND MATERIAL RISK WARNINGS 4 Section II COMPANY PROFILE AND KEY FINANCIAL INDICATORS 8 Section III SUMMARY OF THE COMPANY’S BUSINESS 25 Section IV REPORT OF THE BOARD OF DIRECTORS 33 Section V SIGNIFICANT EVENTS 85 Section VI CHANGES IN ORDINARY SHARES AND PARTICULARS ABOUT SHAREHOLDERS 123 Section VII PREFERENCE SHARES 134 Section VIII DIRECTORS, SUPERVISORS, SENIOR MANAGEMENT AND EMPLOYEES 135 Section IX CORPORATE GOVERNANCE 191 Section X CORPORATE BONDS 233 Section XI FINANCIAL REPORT 242 Section XII DOCUMENTS AVAILABLE FOR INSPECTION 243 Section XIII INFORMATION DISCLOSURES OF SECURITIES COMPANY 244 IMPORTANT NOTICE The Board, the Supervisory Committee, Directors, Supervisors and senior management of the Company warrant the truthfulness, accuracy and completeness of contents of this annual report (the “Report”) and that there is no false representation, misleading statement contained herein or material omission from this Report, for which they will assume joint and several liabilities. This Report was considered and approved at the seventh meeting of the seventh session of the Board. All the Directors of the Company attended the Board meeting. None of the Directors or Supervisors has made any objection to this Report. Deloitte Touche Tohmatsu (Deloitte Touche Tohmatsu and Deloitte Touche Tohmatsu Certified Public Accountants LLP (Special General Partnership)) have audited the annual financial reports of the Company prepared in accordance with PRC GAAP and IFRS respectively, and issued a standard and unqualified audit report of the Company. All financial data in this Report are denominated in RMB unless otherwise indicated.
    [Show full text]
  • Marketgrader India All-Cap Growth Leaders Index
    Fact Sheet MarketGrader MarketGrader India All-Cap Growth Leaders Index RESEARCH & INDEXES The MarketGrader India All-Cap Growth Leaders Index consists of the 80 most fundamentally sound companies with the best growth prospects in India, whose shares are listed in the country’s national exchanges or in the United States. Its objective is to give investors access to the best companies in the world’s fastest growing large economy without overpaying for their shares. Constituents are selected across all market cap segments and all economic sectors after they have passed rigorous size and liquidity filters. Index Rules Performance Investable Universe IndiaCumulative Growth Leaders Total Return, Jan. 2008 - Oct. 2020* All data as of Oct 30, 2020 All companies domiciled in India that have 125% received a MarketGrader Score consistently for at least six months, whose shares are 100% listed on the National Stock Exchange, the Bombay Stock Exchange or on U.S. national 75% exchanges. 50% Regulatory Requirements 25% Stocks are ineligible for Index selection if 0% they are included in the ‘Red Flag List,’ maintained and published by the National -25% Securities Depository Limited (NDSL) of India, or on the ‘Breach List,’ maintained by the -50% Central Depository Services (India) Limited 10/30/2020 -75% (CDSL), both of which govern foreign own- 12/31/07 12/31/08 12/31/09 12/31/10 12/30/11 12/31/12 12/31/13 12/31/14 12/31/15 12/30/16 12/29/17 12/31/18 12/31/19 ership limits of Indian securities. MarketGrader India All-Cap Growth Leaders India S&P BSE SENSEX MSCI India Size Requirements All companies must have a minimum total Calendar Year Returns Annualized Returns market capitalization of USD 150 million on MG India India S&P BSE MSCI MG India India S&P MSCI the Index selection date.
    [Show full text]
  • Results Announcement for the Year Ended December 31, 2020
    (GDR under the symbol "HTSC") RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 The Board of Huatai Securities Co., Ltd. (the "Company") hereby announces the audited results of the Company and its subsidiaries for the year ended December 31, 2020. This announcement contains the full text of the annual results announcement of the Company for 2020. PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND THE ANNUAL REPORT This results announcement of the Company will be available on the website of London Stock Exchange (www.londonstockexchange.com), the website of National Storage Mechanism (data.fca.org.uk/#/nsm/nationalstoragemechanism), and the website of the Company (www.htsc.com.cn), respectively. The annual report of the Company for 2020 will be available on the website of London Stock Exchange (www.londonstockexchange.com), the website of the National Storage Mechanism (data.fca.org.uk/#/nsm/nationalstoragemechanism) and the website of the Company in due course on or before April 30, 2021. DEFINITIONS Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the section headed “Definitions” in the annual report of the Company for 2020 as set out in this announcement. By order of the Board Zhang Hui Joint Company Secretary Jiangsu, the PRC, March 23, 2021 CONTENTS Important Notice ........................................................... 3 Definitions ............................................................... 6 CEO’s Letter .............................................................. 11 Company Profile ........................................................... 15 Summary of the Company’s Business ........................................... 27 Management Discussion and Analysis and Report of the Board ....................... 40 Major Events.............................................................. 112 Changes in Ordinary Shares and Shareholders .................................... 149 Directors, Supervisors, Senior Management and Staff..............................
    [Show full text]
  • Investment Philosophy
    ** 1st NAV Date 6 Nov 2020 - quant ESG Fund; * NAV for For Both Growth & Direct Plan ,NAV Recorded on 08 January 2021 The date March 24, 2020 marks the bottom of the indices after the panic of the pandemic. Above is the performance of the schemes relative to their respective benchmarks since the bottom. With a maximum outperformance of 450bps and a relatively low beta, this is a glimpse of quant’s Equity based schemes performance. quant mutual fund FACTSHEET JANUARY 2021 Table of content quant’s VLRT Outlook 3 Scheme Details . quant Liquid Fund 6 . quant Active Fund 8 . quant Small Cap Fund 10 . quant Tax Plan 12 . quant Mid Cap Fund 14 . quant Large & Mid-Cap Fund 16 . quant Focused Fund 18 . quant Multi Asset Fund 20 . quant ESG Fund 22 . quant Absolute Fund 24 . quant Infrastructure Fund 26 . quant Consumption Fund 28 . quant Dynamic Bond 30 . quant Money Market Fund 32 Dividend History 34 Glossary 35 Point of Service (PoS) Location 37 Disclaimer: The Factsheet is for general reading purpose only and is not meant to serve as a professional guide. This document has been prepared on the basis of publicly available information, internally developed data and other sources believed to be reliable. The Sponsor, the Investment Manager, the Trustee or any of their respective directors, employees, affiliates or representatives (“entities & their affiliates”) do not assume any responsibility for, or warrant the authenticity, accuracy, completeness, adequacy and reliability of such information. Whilst no action has been solicited based upon the information provided herein; due care has been taken to ensure that the facts are accurate and opinions given are fair and reasonable.
    [Show full text]
  • Factory Address Country
    Factory Address Country Durable Plastic Ltd. Mulgaon, Kaligonj, Gazipur, Dhaka Bangladesh Lhotse (BD) Ltd. Plot No. 60&61, Sector -3, Karnaphuli Export Processing Zone, North Potenga, Chittagong Bangladesh Bengal Plastics Ltd. Yearpur, Zirabo Bazar, Savar, Dhaka Bangladesh ASF Sporting Goods Co., Ltd. Km 38.5, National Road No. 3, Thlork Village, Chonrok Commune, Korng Pisey District, Konrrg Pisey, Kampong Speu Cambodia Ningbo Zhongyuan Alljoy Fishing Tackle Co., Ltd. No. 416 Binhai Road, Hangzhou Bay New Zone, Ningbo, Zhejiang China Ningbo Energy Power Tools Co., Ltd. No. 50 Dongbei Road, Dongqiao Industrial Zone, Haishu District, Ningbo, Zhejiang China Junhe Pumps Holding Co., Ltd. Wanzhong Villiage, Jishigang Town, Haishu District, Ningbo, Zhejiang China Skybest Electric Appliance (Suzhou) Co., Ltd. No. 18 Hua Hong Street, Suzhou Industrial Park, Suzhou, Jiangsu China Zhejiang Safun Industrial Co., Ltd. No. 7 Mingyuannan Road, Economic Development Zone, Yongkang, Zhejiang China Zhejiang Dingxin Arts&Crafts Co., Ltd. No. 21 Linxian Road, Baishuiyang Town, Linhai, Zhejiang China Zhejiang Natural Outdoor Goods Inc. Xiacao Village, Pingqiao Town, Tiantai County, Taizhou, Zhejiang China Guangdong Xinbao Electrical Appliances Holdings Co., Ltd. South Zhenghe Road, Leliu Town, Shunde District, Foshan, Guangdong China Yangzhou Juli Sports Articles Co., Ltd. Fudong Village, Xiaoji Town, Jiangdu District, Yangzhou, Jiangsu China Eyarn Lighting Ltd. Yaying Gang, Shixi Village, Shishan Town, Nanhai District, Foshan, Guangdong China Lipan Gift & Lighting Co., Ltd. No. 2 Guliao Road 3, Science Industrial Zone, Tangxia Town, Dongguan, Guangdong China Zhan Jiang Kang Nian Rubber Product Co., Ltd. No. 85 Middle Shen Chuan Road, Zhanjiang, Guangdong China Ansen Electronics Co. Ning Tau Administrative District, Qiao Tau Zhen, Dongguan, Guangdong China Changshu Tongrun Auto Accessory Co., Ltd.
    [Show full text]
  • Transmissibility of Hand, Foot, and Mouth Disease in 97 Counties of Jiangsu Province, China, 2015- 2020
    Transmissibility of Hand, Foot, and Mouth Disease in 97 Counties of Jiangsu Province, China, 2015- 2020 Wei Zhang Xiamen University Jia Rui Xiamen University Xiaoqing Cheng Jiangsu Provincial Center for Disease Control and Prevention Bin Deng Xiamen University Hesong Zhang Xiamen University Lijing Huang Xiamen University Lexin Zhang Xiamen University Simiao Zuo Xiamen University Junru Li Xiamen University XingCheng Huang Xiamen University Yanhua Su Xiamen University Benhua Zhao Xiamen University Yan Niu Chinese Center for Disease Control and Prevention, Beijing City, People’s Republic of China Hongwei Li Xiamen University Jian-li Hu Jiangsu Provincial Center for Disease Control and Prevention Tianmu Chen ( [email protected] ) Page 1/30 Xiamen University Research Article Keywords: Hand foot mouth disease, Jiangsu Province, model, transmissibility, effective reproduction number Posted Date: July 30th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-752604/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/30 Abstract Background: Hand, foot, and mouth disease (HFMD) has been a serious disease burden in the Asia Pacic region represented by China, and the transmission characteristics of HFMD in regions haven’t been clear. This study calculated the transmissibility of HFMD at county levels in Jiangsu Province, China, analyzed the differences of transmissibility and explored the reasons. Methods: We built susceptible-exposed-infectious-asymptomatic-removed (SEIAR) model for seasonal characteristics of HFMD, estimated effective reproduction number (Reff) by tting the incidence of HFMD in 97 counties of Jiangsu Province from 2015 to 2020, compared incidence rate and transmissibility in different counties by non -parametric test, rapid cluster analysis and rank-sum ratio.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Partial List Ex Conference 20
    Artemis Health Institute Bharat Serums & Vaccines Carrier CP Milk & Food Products Discovery FCDO GlaxoSmithkline Henkel India Shelter Finance Corporation Kadtech Infraprojects LSEG MIND NIIT Paytm Money PT Bank BTPN RTI Shyam Spectra Stryker ThoughtWorks ValueMined Technologies Y-Axis Solutions Arth Group Bharti Axa Life Insurance Cars24 CP Plus Dksh FE fundinfo Glenmark Pharmaceuticals Herbalife Nutition IndiaMART Kaivalya Educatiion Foundation LTI MindTickle Nineleaps technology solutions PayU PT. Media Indra Buana Ruby Seven Studios Shyam Spectra STT Global Data Centres Thryve Digital Valuex Technologies Yamaha Motor Arvind Fashions Bhel Caterpillar CP Wholesale DLF Fedex GlobalEdge Here Technologies Indigo Kalpataru Luminous Power Technologies Mindtree Nippon Koei PCCPL PTC Network Rustomjee Sidel Successive Technologies Tierra Agrotech Varroc Engineering Yanbal Asahi India Glass BIC CDK Global CPI DMD ADVOCATES Ferns n Petals GlobalLogic Herman Miller Indmoney Kama Ayurveda Luthra Group MiQ Digital NISA Global PCS Publicis Media S P Setia Siemens Sulzer Pumps Tifc Varuna Group Yanmar TAKE A LOOK AT LIST OF Ashirvad Pipes Bidgely Technologies CEAT Creditas Solutions DP World Ferrero GMR Hero Indofil industries Kanishk Hospital Luxury Personified Mizuho Bank Nissan Peak Infrastructure Management PUMA Group S&P Global Sigma AVIT Infra Services Summit Digitel Infrastructure TIL Vastu Housing Finance Corpora- Yara COMPANIES WHO WILL JOIN Asian paints Bigtree Entertainment Celio Cremica Dr Reddy's Ferring Pharmaceuticals Godrej & Boyce
    [Show full text]